Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ODC1 | P11926 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.40 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11301547 | 0.89 | CYP3A4 (0.50) | CYP3A4ALDH1A1TSHRITPR3ITPR1 | |
| SCHEMBL28706 | 0.89 | CYP3A4 (0.50) | CYP3A4ALDH1A1TSHRITPR3ITPR1 | |
| SCHEMBL481712 | 0.89 | CYP3A4 (0.50) | CYP3A4ALDH1A1TSHRITPR3ITPR1 | |
| SCHEMBL5462392 | 0.88 | TSHR (0.59) | CYP3A4ALDH1A1TSHRITPR3ITPR1 | |
| SCHEMBL28567051 | 0.88 | CYP3A4 (0.77) | CYP3A4TSHRGABBR2GABBR1 | |
| SCHEMBL28200675 | 0.85 | CYP3A4 (0.46) | CYP3A4ALDH1A1ODC1TSHRITPR3 | |
| SCHEMBL555003 | 0.81 | ALDH1A1 (0.50) | CYP3A4ALDH1A1TSHR | |
| Ethylenediamine SCHEMBL31533530 | 0.81 | CYP3A4 (0.85) | CYP3A4TSHR | |
| SCHEMBL16187636 | 0.81 | TSHR (0.56) | CYP3A4ALDH1A1TSHRGABBR2CYP1A2 | |
| Oxalic Acid SCHEMBL31481130 | 0.79 | TSHR (0.48) | CYP3A4ALDH1A1TSHRITPR3ITPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2574 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3536307-B1 | DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS | ALLERGAN IND SAS (FR) | 2021-10-20 | — | — | EP | claimed |
| EP-2895607-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | claimed |
| CN-106701758-B | Modulation of HSP47 expression | 日东电工株式会社 | 2020-02-07 | — | — | CN | claimed |
| EP-2714002-B1 | DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS | ALLERGAN INC (US) | 2019-04-03 | — | — | EP | claimed |
| EP-3434773-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2019-01-30 | — | — | EP | claimed |
| US-10093923-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2018-10-09 | — | — | US | claimed |
| US-9611474-B2 | Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | claimed |
| EP-3012324-A2 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Corporation (JP) | 2016-04-27 | — | — | EP | claimed |
| US-20160108399-A1 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2016-04-21 | — | — | US | claimed |
| US-9206424-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2015-12-08 | — | — | US | claimed |
| EP-1115859-A2 | HAIRPIN HYBRIDIZER MOLECULES FOR MODULATION OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | claimed |
| EP-1098969-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1071753-A2 | NUCLEIC ACID MOLECULES WITH NOVEL CHEMICAL COMPOSITIONS CAPABLE OF MODULATING GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-01-31 | — | — | EP | claimed |
| WO-2000017346-A2 | HAIRPIN HYBRIDIZER MOLECULES FOR MODULATION OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-03-30 | — | — | WO | claimed |
| WO-2000004141-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |
| US-5998203-A | PARTICULARLY USEFUL FOR ENZYMATIC CLEAVAGE OF RNA OR SINGLE-STRANDED DNA. | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | claimed |
| WO-1999054459-A2 | NUCLEIC ACID MOLECULES WITH NOVEL CHEMICAL COMPOSITIONS CAPABLE OF MODULATING GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-28 | — | — | WO | claimed |
| EP-0886641-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-30 | — | — | EP | claimed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | claimed |